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Abstract
Recent observations that aberrant expression of tissue transglutaminase (TG2) promotes growth, survival, and metastasis of
multiple tumor types is of great significance and could yield novel therapeutic targets for improved patient outcomes. To
accomplish this, a clear understanding of how TG2 contributes to these phenotypes is essential. Using mammary epithelial
cell lines (MCF10A, MCF12A, MCF7 and MCF7/RT) as a model system, we determined the impact of TG2 expression on cell
growth, cell survival, invasion, and differentiation. Our results show that TG2 expression promotes drug resistance and
invasive functions by inducing epithelial-mesenchymal transition (EMT). Thus, TG2 expression supported anchorage-
independent growth of mammary epithelial cells in soft-agar, disrupted the apical-basal polarity, and resulted in
disorganized acini structures when grown in 3D-culture. At molecular level, TG2 expression resulted in loss of E-cadherin
and increased the expression of various transcriptional repressors (Snail1, Zeb1, Zeb2 and Twist1). Tumor growth factor-beta
(TGF-b) failed to induce EMT in cells lacking TG2 expression, suggesting that TG2 is a downstream effector of TGF-b-induced
EMT. Moreover, TG2 expression induced stem cell-like phenotype in mammary epithelial cells as revealed by enrichment of
CD44
+/CD24
-/low cell populations. Overall, our studies show that aberrant expression of TG2 is sufficient for inducing EMT in
epithelial cells and establish a strong link between TG2 expression and progression of metastatic breast disease.
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Introduction
Tumor cell resistance to systemic therapies and metastasis to
distant tissues pose major impediment to successful treatment of
breast cancer [1]. Therefore, understanding the molecular
mechanisms that contribute to the development of drug resistance
and facilitate metastasis could provide valuable targets for effective
control and treatment of the disease. Transglutaminase 2 (TG2), a
pro-inflammatory protein, has received considerable attention
recently for its potential role in cancer cells. There is ample
evidence supporting that metastatic and drug-resistant breast
cancer cells express high basal levels of TG2 [2] and that its
expression is associated with increased cell survival, invasion and
motility of cancer cells [3] . However, the knowledge on how TG2
promotes these phenotypes remains elusive.
TG2 is a multifunctional protein implicated in diverse
physiological and pathological processes [4]. In addition to
transamidation activity, TG2 can catalyze GTPase [5], protein
disulfide isomerase [6] and kinase activities [7]. In normal tissues,
TG2 expression is upregulated in response to tissue injury and
other stressors; there it plays a role in restoring the normal
homeostasis [8]. In such pathological conditions as tissue fibrosis
and cancer, TG2 expression within the cell or its microenviron-
ment promotes cell adhesion and modulates intracellular signaling
[9]. For example, intracellular TG2 is known to activate focal
adhesion kinase (FAK), protein kinase B, and Akt [10], cyclic AMP
response-element binding protein [11] , platelet-derived growth
factor [12], and the nuclear factor-kB (NF-kB) [13] . In the
extracellular environment, TG2 can modify the extracellular
matrix proteins and alter cell-cell (homotypic) and cell-matrix
(heterotypic) interactions [14]. Although, emerging lines of
evidence suggest a close link between TG2, drug resistance, and
metastasis of cancer cells, the pathways that contribute to these
events remain largely unknown.
Recently epithelial-to-mesenchymal transition (EMT), which
shares many molecular characteristics with cancer stem cells, has
been implicated to play a role in cancer metastasis [15,16]. EMT
is a complex dynamic process that occurs during embryonic
development for reprogramming of epithelial cells [16]. Its
reactivation during adult life has been associated with patholog-
ical conditions, such as inflammation, fibrosis, and cancer [16,17].
The EMT promotes the detachment of cancer cells from the
primary tumor andfacilitatesmigration via loss of cellular polarity
and adhesion [17]. Moreover, emerging evidence suggests a
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13390strong link between EMT and chemoresistance and radioresis-
tance [17,18]. Therefore, understanding of molecular mecha-
n i s m st h a tl e a dt oE M Ti si m p o r t a n tf o rd e s i g n i n gn o v e l
therapeutic strategies for increasing drug sensitivity and the
suppression of metastasis toward better treatment outcomes in
cancer patients.
Here we demonstrate that aberrant expression of the pro-
inflammatory protein, TG2, in mammary epithelial cells (MECs)
is associated with loss of E-cadherin, cellular polarity, upregula-
tion of mesenchymal markers, such as fibronectin, vimentin, N-
cadherin and transcriptional repressors, such as Snail1, Zeb1,
Zeb2 and Twist1. Moreover, our data suggest that TG2 is a
downstream mediator of tumor growth factor-beta (TGF-b)-
induced EMT. We conclude that TG2 expression signals the
onset of EMT in epithelial cells and contributes to their
increased survival and metastatic potential and hence represents
a promising therapeutic target for drug-resistant and metastatic
breast cancer.
Results
TG2 induces EMT in mammary epithelial cells
We previously reported that metastatic breast cancer cells express
high basallevelsofTG2[2]andthat increasedexpressionofTG2in
breast cancer cells contributes to their increased survival, invasion,
motility and drug resistance [2,3]. To understand the role of TG2 in
metastatic transformation, we stably transfected TG2 into a non-
transformed human breast mammary epithelial cell line MCF10A.
TG2-overexpressing MCF-10A cells (10A-TG2) showed marked
changes in their morphology compared to the vector-transfected
(10A.Vec) cells. As shown in Fig. 1A, 10A-Vec cells appeared
rounded with cobblestone epithelial morphology and grewas tightly
connected clusters. 10A-TG2 cells, in contrast, displayed spindle-
like shape and exhibited scattered distribution of fibroblast-like cells
with disrupted cell-to-cell adhesion (Fig. 1A). Expression of TG2 in
these cells was confirmed by immunoblotting (Fig. 1B) and
immunostaining (Fig. 1C). The mesenchymal nature of 10A-TG2
Figure 1. TG2 induces EMT in mammary epithelial cells. MCF10A and MCF12A cells were stably transfected with vector alone (10A-Vec and
12A-Vec) or lentiviral-TG2 construct (10A-TG2 and 12A-TG2). (A) Phase-contrast images of 10A-Vec and 10A-TG2 cells after 48 hr culture in medium.
Magnification 10X. (B) Immunoblot showing relative expression of TG2 in 10A-Vec and 10A-TG2 cells. (C) Immunofluorescence due to TG2 and EMT
markers in 10A-Vec (top panel) and 10A-TG2 (bottom panel) cells. Green fluorescence shows the expression and localization of indicated proteins and
DAPI (blue) staining shows the nuclei. (D) Immunoblot analysis of the indicated EMT markers in 10A-Vec and 10A-TG2 cells. Expression of epithelial
cell markers (E-cadherin, b-catenin) and mesenchymal cell marker (N-cadherin, fibronectin, and vimentin) was examined by immunoblotting. (E)
Morphology (left penal) and immunoblot analysis of TG2, epithelial marker (E-cadherin) and mesenchymal marker (fibronectin) expression in 12A-vec
and 12A-TG2 cells. (F) Morphology (left penal) and immunoblot analysis for constitutive TG2, epithelial marker (E-cadherin) and mesenchymal marker
(fibronectin) expression in drug-sensitive and drug-resistant (RT) MCF-7 cells. Multiple stable polyclones were established from MCF10A and MCF12A
cells and experiments were repeated multiple times with similar results using different clones.
doi:10.1371/journal.pone.0013390.g001
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(SupplementalFig.S1).TheseresultssuggestedthatTG2expression
in epithelial cells is associated with their transition into mesenchy-
mal cells.
The morphological changes during EMT are driven by a
number of molecular alterations, including loss or decrease of
epithelial cell markers (e.g., E-cadherin and b-catenin) and de novo
expression of mesenchymal markers (e.g., N-cadherin, vimentin,
and fibronectin) [17]. Indeed, 10A-vec cells expressed high levels
of E-cadherin and b-catenin (Fig. 1C and D) but low or
undetectable levels of fibronectin (Fig. 1C and D), vimentin and
N-cadherin (Fig. 1D). 10A-TG2 cells, in contrast, showed almost
complete loss of E-cadherin and reduced expression of b-catenin
(Fig. 1C and D). Similarly, the expression of fibronectin (Fig. 1C
and D), N-cadherin and vimentin (Fig. 1D) was upregulated in
10A-TG2 cells. 10A-vec cells showed membranous staining of E-
cadherin and b-catenin but no staining for fibronectin (Fig. 1C).
In contrast, 10A-TG2 cells showed loss of E-cadherin staining,
reduced cytoplasmic b-catenin and increased fibronectin staining
(Fig. 1C). To rule out that TG2-induced EMT is not unique to
MCF10A cells, we also determined the effect of TG2 expression
in another non-transformed human breast mammary epithelial
cell line, MCF12A. Results shown in Figure 1E revealed similar
changes in the morphology, E-cadherin, and fibronectin expres-
sion in response to TG2 in these cells. Moreover, drug-resistant
MCF-7/RT cells, which express high constitutive levels of TG2
[19], exhibited similar fibroblast-like morphology, down regula-
tion of E-cadherin and gain of fibronectin expression when
compared with their TG2-deficient, drug-sensitive counterpart
MCF-7 cells (Fig. 1F). These results implied that TG2 expression
results in the loss of cell-cell adhesion by inducing EMT in
mammary epithelial cells.
TG2 expression is associated with increase in Snail1,
Twist1 and Zeb1
Induction of EMT is orchestrated by various transcription
factors including Snail1, Slug, Twist, Zeb1, Zeb2, E12, E47 [20].
To determine which of these transcription factors are involved in
TG2-induced EMT, we next performed transcriptional profiling
of EMT-associated genes using the SABiosceinces’ real-time
PCR-based EMT array. Figure 2A shows the relative expression
of EMT-associated genes in 10A-TG2 cells with respect to 10A-
vec cells. The epithelial markers E-cadherin (CDH1), desmocol-
lin 2, Krt 19, Krt14, Krt7, desmoplakin and occludin were
downregulated whereas, the mesenchymal markers N-cadherin,
versican, fibronectin, Sparc, and vimentin were upregulated.
These results suggest that loss of E-cadherin and upregulation of
N-cadherin (CDH2), fibronectin and vimentin in 10A-TG2 cells
was regulated at the transcriptional level. To further validate
these results, we performed RT-PCR for E-cadherin, N-
cadherin, fibronectin and vimentin in 10A-vec and 10A-TG2
cells. Results shown in Figure 2B confirmed that TG2 expression
was associated with a complete loss of E-cadherin transcript and
increase in N-cadherin, fibronectin, and vimentin transcripts.
Accordingly, 10A-TG2 cells showed a significant increase in the
transcript levels of Snail1, Zeb1, Zeb2,a n dTwist1 ( F i g .2 A ) ,t h e
known transcriptional repressors of E-cadherin and inducers of
N-cadherin, fibronectin, and vimentin. Similar results were
obtained for Snail1, Zeb1, and Twist1 expression by RT-PCR
(Fig. 2C, left panel) and western blot (Fig. 2C, right panel). These
results suggested that TG2 expression induced transcriptional
repression of E-cadherin and transactivation of fibronectin, N-
cadherin, and vimentin by altering Snail1, Zeb1, Zeb2, and
Twist1 levels.
TG2-induced EMT confers invasiveness, drug resistance
and tumorigenic phenotype
Based on the biological contexts, EMT has been classified into
three subtypes: Type 1 is associated with embryonic development
and neither causes fibrosis nor induces invasive phenotype. Type 2
EMT is associated with wound healing, tissue regeneration, and
organ fibrosis and does not induce the invasiveness. Type 3 or
oncogenic-EMT is associated with cancer and is characterized by
acquisition of invasive and metastatic functions [21]. Accordingly,
TG2 expression was associated with increased invasiveness of 10A-
TG2 cells compared to the 10A-vec cells (Figs. 3A). These results
suggest that TG2-induced EMT is the Type 3 and is associated with
the acquisition of invasive and metastatic potential. As a result, we
next determined weather TG2-induced EMT would promote the
growth of 10A-TG2 cells in soft agar – an in vitro surrogate measure
of tumorigenicity [22]. Results shown in Fig. 3B demonstrated that
10A-TG2 cells could grow and form colonies in soft agar whereas,
10A-vec cells failed to survive under these conditions.
MCF10A is a non-transformed human mammary epithelial cell
line and is an excellent in vitro model to study mammary gland
development and breast cancer progression in 3D cultures. These
cells form well-organized acinar structures that mimic the normal
mammary end bud in vivo [23]. We used this 3D model to
determine weather TG2-induced EMT can disrupt the organiza-
tion of MCF10A cells. As shown in Fig. 3C, the 10A-vec cells grew
into well-organized acinar-like structures with hollow lumens
(Fig. 3C and D, top panel). Immunostaining of spheroids with anti-
laminin V antibody revealed the presence of continuous and well-
defined basement membrane surrounding the acini with apicoba-
sal polarization of cells (Fig. 3D). Similarly, immunostaining of
spheroids for E-cadherin further confirmed the apico-basal
polarization with cell-to-cell contact in acinar structures (Fig. 3D).
The 10A-TG2 cells, in contrast, demonstrated severe disruption
of acinar architecture, characterized by irregular spheroid growth
and no lumen formation (Figs. 3C and 3D, lower panels). A
distinct feature of 10A-TG2 sheroids was the gain of invasive
function; many cells escaped from the acini and invaded the
surrounding matrix (Fig. 3C, inset). Similarly, immunostaining for
laminin V and E-cadherin revealed diffused basement membrane
formation and complete loss of E-cadherin in10A-TG2 acini
(Fig. 3D). Similar changes in growth pattern and organization of
acinar structure were observed in TG2-expressing MCF-12A cells,
when grown in 3D culture (Supplemental Fig. S2). These results
further supported the ability of TG2 to promote invasive potential
in MECs. Several lines of evidence suggest that tumor cells
undergoing EMT, become resistant to chemotherapy and
conversely tumor cells selected for drug resistance exhibit EMT
phenotype [17]. Therefore, we next determined weather TG2-
induced EMT in MCF-10A cells could confer resistance to
chemotherapeutic drug. Results shown in Fig. 3E demonstrated
that 10A-TG2 cells were relatively more resistant to doxorubicin-
induced cell death compared to the10A-vec cells. Overall, these
results suggest that TG2-induced EMT promotes invasiveness,
drug resistance and anchorage-independent growth of MECs.
TG2 is a downstream mediator of TGF-b-induced EMT
Because the EMT gene signature of 10A-TG2 cells (Fig. 2A)
closely matched the TGF-b-induced EMT gene signature [24], we
next determined whether TG2-induced EMT involved TGF-b
signaling. For this purpose, we checked the expression of TGF-b
receptor-1 and -2 and phospho-smad 2 and 3 in 10A-vec and 10A-
TG2 cells. Interestingly, we did not observe any change in
receptors level or phosphorylation status of smad-2 or samd-3
(Supplemental Fig. S3), suggesting that TG2-induced EMT is
TG2-Induced EMT
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program is regulated by a series of intracellular signaling
molecules, such as NF-kB, MAPK, PI3K, Akt, RhoB, Ras, and
c-Fos as well as by cell-surface proteins, such as b4 integrin, a5b1
integrin, and aVb6 integrin [25]. Previous studies have shown that
TG2 expression results in constitutive activation of NF-kB [13,26].
Therefore, next we determined the status of NF-kB activity in
10A-vec and 10A-TG2 cells. Results shown in Fig. 4A reveled
almost 4-fold increase in NF-kB activity in 10A-TG2 cells
compared with the 10A-vec cells. These results suggest that
TG2-induced activation of NF-kB may be responsible for
transcriptional regulation of Snail1 and induction of EMT in
10A-TG2 cells. Indeed, TG2 was recently shown to associate with
NF-kB for its recruitment to the promoter sequence of Snail and
leading to its transcriptional regulation [27].
We also determined the status of pFAK and pAkt, the other
known mediators of EMT [28], in MCF10A sublines. Results
shown in Fig. 4B demonstrated the constitutive activation of both
FAK and Akt in 10A-TG2 cells. These results suggest that TG2-
mediated activation of FAK, Akt and NF-kB may play a role in
drivingMCF10AcellsintoEMTbyregulating Snail,Zeb1,andTwist
genes expression. Because TGF-b can induce TG2 expression [29],
we next determined whether TG2 expression is required for TGF-b
to induceEMT. MCF10A cells stablytransfectedwithTG2-shRNA
and treated with TGF-b showed no or minimal change in their
morphology (Fig. 4C). In contrast, MCF10A-control shRNA-
transfected cells under similar conditions, revealed progressive
change in their morphology starting as early as 4 days post-TGFb
treatment. After 12-days of treatment, they appeared elongated and
showed mesenchymal appearance (Fig. 4C). Western blot analysis
for epithelial markers in TGF-b-treated MCF10A-control-shRNA
cells revealed downregulation of E-cadherin on day 4 with complete
loss by day 8 of treatment. No such change in E-cadherin level was
evident in TG2shRNA-transfected cells even after 12 days of
Figure 2. TG2 expression results in altered expression of Snail1, Twist1, Zeb1, and Zeb2. (A) Real time RT-PCR array showing relative
changes in the expression of EMT-related genes in 10A-TG2 cells in comparison to 10A-Vec cells. Y-axis denotes the fold- expression and x-axis
denotes the genes. The expression of GAPDH, b-actin and 18S ribosomal RNA was used to normalize variable template loading. (B) RT-PCR analysis
for EMT-related transcripts was used to validate their expression in 10A-Vec and 10A-TG2 cells. (C) RT-PCR (left panel) and immunoblot (right panel)
analysis was performed to validate the expression of transcription factors Snail1, Zeb1 and Twist1 in 10A-Vec and 10A-TG2 cells. Results shown are
from a representative experiment repeated at least twice with similar results.
doi:10.1371/journal.pone.0013390.g002
TG2-Induced EMT
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treatment was found upregulated but only in MCF10A-control
shRNA cells (Fig. 4D). Similarly, downregulation of endogenous (in
MCF-7/RT cells) or induced TG2 (in MCF-10A/TG2 cells)
reversed the EMT process (mesenchymal-to-epithelial) as revealed
by increase in E-cadherin and decrease in fibronectin expression
(Fig. 4E). These results clearly implied that TG2 is a downstream
mediator of TGF-b-induced EMT.
TG2-induced EMT promotes stem cell-like phenotype
Based on recent reports that induction of EMT results in
acquisition of stem cell-like characteristics and that EMT and stem
Figure 3. TG2-induced EMT confers invasiveness, drug resistance, and tumorigenic phenotype. (A) Transwell-Matrigel invasion assay
was performed with 10A-Vec and 10A-TG2 cells. Cells that invaded though the Matrigel after 72 hr incubation were counted in five random
microscopic fields under 20X magnification. Experiments were done three times in triplicate. Results shown are the average number of invading cells
per field 6 SEM. (B) Graph represents average number of colonies formed from three independent experiments 6 SEM after 3 weeks’ incubation of
cells in soft agar. Images of colonies formed from a representative experiment after 3 weeks culture in soft agar are shown in right panel.
Magnification 10X. (C) Phase-contrast images of acinar structures (4 and 12 days) formed as a result of 10A-Vec and 10A-TG2 cell culture in Matrigel-
coated glass-slide chambers for indicated time periods. Inset, amplified view of individual MCF10A-TG2 cells invading the surrounding Matrigel
(indicated by the arrow). (D) Loss of basement membrane integrity and cell-to-cell adhesion in 10A-TG2 acini. MCF10A cells were cultured in Matrigel-
coated chambers for 12 days and immunostained for laminin V and E-cadherin (green) and DAPI (blue). Representative images from two independent
experiments with similar results are shown. Magnifications 20X. (E) Sensitivity of 10A-Vec and 10A-TG2 cells to doxorubicin. Quadruplicate wells in 96-
well plates, containing 2,000 cells per well in 0.2 ml of the complete medium (10% FCS) were either left untreated or treated with indicated
concentrations of doxorubicin. Two days after the treatment, viable cells remaining in wells were determined by MTS reduction test, and percent cell
viability was calculated. Experiments were repeated at least three times with similar results. Bars, mean of quadruplicate values from a representative
experiment; lines, SD.
doi:10.1371/journal.pone.0013390.g003
TG2-Induced EMT
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[30],nextwedeterminedwhether TG2-inducedEMTcould induce
a stem cell state in MCF10A cells. We used flow cytometric analysis
to determine the expression of CD44
high/CD24
-/low phenotype in
10A-TG2 and 10A-vec cells. The CD44
high/CD24
-/low has been
used as a marker to isolate stem cells from normal and cancerous
mammary epithelial cells [31]. Results from a representative
experiment shown in Fig. 5A revealed that significantly more
10A-TG2 cells expressed CD44
high/CD24
-/low stem cell markers.
Consistent with these results was the observation that CD326
antigen, an epithelial marker, was significantly downregulated in
10A-TG2 cells. To further validate these results, we next analyzed
the CD44
high/CD24
-/low expression in doxorubicin-resistant MCF-7/
RT breast cancer cells [19]. The constitutive expression of TG2 in
MCF-7/RT cells was associated with a similar enrichment of
CD44
high/CD24
-/low cell population compared to the parental drug-
sensitive and TG2-deficient MCF-7 cells (Fig. 5B). However, as the
MCF-7/RT subline represents a small subclone of MCF-7 cells,
association between TG2 expression and CD44
high/CD24
-/low
phenotype needs to be further validated. Nevertheless, TG2 expression
in yet another mammary epithelial cell line (MCF12A), showed a
similar enrichment in CD44
high/CD24
-/low expressing cells compared
Figure 4. TG2 is a downstream mediator of TGF-b-induced EMT. (A) Supershift assay for NF-kB activity using EMSA with the nuclear extracts
prepared from indicated cells. Nuclear extracts were incubated with an anti-p65 antibody and anti-p50 antibody, or nonradioactive (cold) or mutant NF-
kB oligonucleotides and examined for DNA binding. Nuclear extract of KMB cells treated with TNF-a (+TNF) were used in parallel as positive control. (B)
Immunoblot analysis showing the level for pAKT(S473) and pFAK(Y397) in 10A-Vec and 10A-TG2 cells. (C) Phase-contrast images of MCF10A cells
transfected with control-shRNA or TG2-shRNA and incubated with 2.5 ng/ml recombinant TGF-b for indicated time periods. After 8 and 12 days of TGF-
b-treatment MCF10A-control-shRNA cells showed mesenchymal morphology but not the TG2-shRNA transfected cells. (D) Immunoblot analysis for
expression of TG2, E-cadherin andfibronectin in MCF10A-control-shRNA and MCF10A-TG2-shRNA cells in response to TGF-b treatment at indicated time
points. (E) Downregulation of endogenous (MCF-7/RT) or induced (MCF10A-TG2) TG2 by siRNA resulted in loss of fibronectin (mesenchemyal marker)
and upregulation of E-cadherin (epithelial marker) expression. Results shown are from a representative experiment repeated twice with similar results.
doi:10.1371/journal.pone.0013390.g004
TG2-Induced EMT
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together, these results suggest a novel TG2-regulated pathway that
could confer EMT and stem cell-like phenotype in mammary epithelial
cells.
Discussion
In this study, we show that aberrant expression of TG2 plays a
critical role in promoting the EMT and EMT-dependent processes
Figure 5. TG2-induced EMT promotes stem cell-like phenotype. FACS analysis of cell surface markers CD326, CD45, CD44 and CD24 in
MCF10A (A) and MCF-7 (B) breast epithelial cells, expressing exogenous (10A-TG2) or endogenous (MCF-7/RT) TG2. 10A-Vec and MCF-7 cells, which
lack TG2 expression, served as controls. Results shown are from a representative experiment repeated multiple times on different occasions.
doi:10.1371/journal.pone.0013390.g005
TG2-Induced EMT
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epithelial cells was associated with increased invasion, loss of cell
polarity, increased cell survival, anchorage-independent growth
and resistance to chemotherapy. Our study provides first evidence
on the functional significance of previously observed increased
TG2 expression in drug resistant and metastatic tumors
[2,3,11,19,26,32].
Many recent reports have demonstrated elevated expression of
TG2 in multiple metastatic tumors and those resistant to
chemotherapy [2,3,11,33–36] and its expression has been
implicated in disease progression. [33,35]. Thus, the observation
that silencing of TG2 gene expression due to hypermethylation of
the CpG island that overlaps transcriptional and translational start
site of TG2 may explain relative sensitivity of primary tumors to
chemotherapeutic drugs [36]. These findings suggest an intercon-
necting link between TG2 expression and progression of
metastatic and drug-resistant cancer.
TG2 is structurally and functionally a complex protein.
Depending on the cellular context, it can promote or suppress
tumor growth [33]. Anti-tumorigenic function of TG2 are mainly
linked to its ability to irreversibly crosslink proteins, which requires
the presence of high calcium ($1 mM) and low GTP (#9 mM).
Therefore, under the physiological conditions intracellular TG2
predominantly exists as a catalytically inactive protein due to low
calcium and inhibitory effect of GTP [37]. Recent understanding
of the molecular pathways that govern the progression of primary
tumors to metastatic disease, points to the EMT as a central stage.
The EMT is considered to be an essential process for development
of different tissues during embryogenesis [17]. Its reactivation in
adults can be considered as a physiological event to control
inflammatory response and heal damaged tissues. However, in
pathological context, such as in tumors or during organ fibrosis,
this healing response may act in a harmful manner and result in
metastasis and organ failure. The evidence is accumulating that
prolonged induction of EMT plays an important role in cancer
progression by converting immobile epithelial cells into fibroblast-
like cells with reduced intercellular adhesion, increased motility
and invasive behavior of cells [15–18,20,21]. Our current findings
that stable expression of TG2 promotes drug resistance and
invasiveness in normal and transformed mammary epithelial cells
by inducing EMT suggest that TG2 serves as a converging point in
conferring drug resistance and metastatic phenotype in cancer
cells. A similar correlation between TG2-induced EMT and
metastasis was recently observed in ovarian cancer cells. [38]
Metastasis of primary tumors to distant sites involves many steps
including, successful invasion, intravasation, survival in circulation,
extravasation and colonization by the cancer cells. Many cancer cell
types rely on the EMT program for successful execution of these
steps [17]. In order for cancer cells to break away from neighboring
cells and invade adjacent cell layers, these tumor cells must lose cell-
cell adhesion and acquire motility. EMT causes loss of epithelial
markers like E-cadherin, desmocollin, desmoplakin, and occluding
(involved in the formation tight connection between them) which
loosens the cell-cell adhesion and helps in the dissemination of cells.
It can modulate other adhesion systems and trigger the remodeling
of the actin cytoskeleton, leading to the mesenchymal phenotype
and increased scattering and motility of carcinoma cells [39].
Acquisition of the mesenchymal phenotype has also been associated
with invasive behavior [40]. Indeed we observed that TG2 induced
EMT in mammary epithelial cells increases the invasive potential
and disrupts the organized growth in 3D culture. Induction of EMT
in both normal and pathological conditions is choreographed by a
set of EMT inducing transcription repressors, such as Snail, Slug,
Twist, Zeb1, and Zeb2. Apart from inducing the EMT program
these transcription factors also confer resistance to cell death,
including resistance to chemotherapeutic drugs [17]. We found
upregulation of some of these transcription factors (Snail1, Twist1,
Zeb1, Zeb2) in TG2 expressing cells that was associated with
increased resistance to doxorubicin. These observations suggest that
TG2-induced EMT promotes drug resistance, an important trait of
metastatic cancer cells.
Once detached form the original niche transformed epithelial
cells need to acquire autonomy from growth regulatory mecha-
nisms, which could give them the survival advantage. Normal
epithelial cells die due to anoikis when detached form the
neighboring cells. EMT promotes anchorage-independent growth
in transformed mammary epithelial cells [30], a property that
generally distinguishes transformed (tumorigenic) from normal
(nontumorigenic) cells [22]. In this study we found that TG2-
induced EMT promotes the anchorage-independent growth and
protects mammary epithelial cells from death. TG2 is known to
rescue cells from anoikis [41], which may explain the ability of
MCF-10A-TG2 cells to grow in anchorage-independent manner.
After successful invasion, intravasation, survival in circulation, and
extrvasation, transformed epithelial cells must survive and colonize
in the hostile environments of the foreign tissue. This process
involves the growth of micrometastases into macroscopic metas-
tases. Recently, it has been proposed that EMT can enable cancer
cells not only to disseminate but also to acquire the ability of self-
renewal by inducing a stem cell state [30]. In line with these
observations, our initial results suggested that TG2-induced EMT
in mammary epithelial cells could confer a stem cell-like
phenotype (CD44
high/CD24
-/low). Currently we are determining
the stem cell characteristics of TG2-transfected MCF10A and
MCF12A cells by establishing their ability to self-renewal and to
differentiate into multiple lineages.
While studies presented here clearly demonstrate the impor-
tance of TG2 in promoting the EMT in mammry epithelial cells,
we are still working on the molecular intricacies through which
TG2 modulates these functions. Previous reports as well as the
current study demonstrate that aberrant expression of TG2 in
epithelial cells results in constitutive activation of FAK, Akt, and
NF-kB [10,13,26]. These pathways are known to be intimately
involved in regulation of EMT, conferring drug resistance, and
promoting metastasis [18,21,42]. For example, activated NF-kBi s
considered to be a hallmark of many advanced-stage tumors
[43,44]. Thus, constitutively active NF-kB is implicated to play a
role in resistance to death-inducing stimuli, including chemother-
apeutic agents [45] and to promote metastasis by inducing EMT
[42]. The NF-kB-induced EMT has been attributed to the
increased stability of Snail due to increased synthesis of ICOP9
signolosome 2, which blocks the ubiqutination and subsequent
degradation of Snail [46]. In another report, constitutive
activation of NF-kB in MCF10A cells was found to induce the
EMT as a result of increased expression of Zeb1 and Zeb2 [47].
Based on these observations it is reasonable to believe that TG2-
induced EMT may result from constitutive activation of NF-kB
and subsequent increase in Snail, Zeb1, and Zeb2 expression, as
observed in this study. Indeed, TG2 was recently shown to
associate with NF-kB for its recruitment to the promoter sequence
of Snail and leading to its transcriptional regulation [27]. Similarly
TGF-b, which is considered to be a potent inducer of EMT both
in normal and pathological conditions [17,24], can cross-talk with
TG2. Thus, TGF-b can induce TG2 expression [48,49] and TG2
can activate TGF-b [50]. Although, we did not observe any
activation of TGF-b signaling in TG2-transfected MCF10A cells,
nevertheless, TGF-b failed to induce EMT in absence of TG2,
suggesting that TG2 is an important downstream mediator of
TG2-Induced EMT
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further validate tumorigenic potential of MCF10A-TG2 cells, our
in vitro data clearly support that stable expression of TG2 is
sufficient to induce metastatic phenotype. Based on these results,
we hypothesize a model that aberrant expression of TG2
contributes to the transformation of primary breast cancer to
metastatic capabilities (Fig. 6). These results also support our belief
that TG2 is a promising therapeutic target for drug-resistant and
metastatic breast cancer.
Methods
Cell lines and vectors
The immortalized human mammary epithelial cells (MCF10A
and MCF12A) and breast cancer cell line MCF7 and MCF7-RT
were maintained as previously described [23,19]. TG2 gene was
subcloned into pCDH lentiviral vector (System Biosciences,
Frederick, MD) from pcDNA3.1-TG2 vector (kindly provided by
Dr. Gail Johnson, University of Rochester, NY). Control ShRNA
and TG2 shRNA lentiviral particles were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). 10A-Vec and 10A-TG2
cells were made by retroviral infection. Retroviral infection of cells
and their 3D culture were done as previously described [23].
Stable clones were selected against 800 ng/ml puromycin.
Multiple stable clones were used to rule out potential clonal
effects. All experiments were performed between passage 5 and 25.
Lentivirus production and infection, and reagents used, are
described in the Supplemental Procedures S1 and Table S2. For
transient transfection TG2-specific siRNA and control siRNA
were purchased from Qiagen (Valencia, CA) and MCF7/RT and
10A-TG2 cells were transfected as described earlier (3). For TGF-
b treatment, MCF10A-control-shRNA and MCF10A-TG2
shRNA cells were cultured in MCF10A medium and treated with
2.5 ng/ml of recombinant-TGFb1 (kindly provided by Dr. Bharat
Aggarwal, M. D. Anderson Cancer Center) for up to 12 days.
Antibodies, Western Blotting, and Immunofluorescence
For Western blots, cells were lysed on ice in 50 mM Tris-HCl
buffer, pH 7.5 containing 150 mM NaCl and 0.5% NP-40. Fifty
micrograms of total protein from each sample were resolved on a
4%–12% SDS Bis-Tris-polyacrylamide gel with running buffer
and transferred onto nitrocellulose membranes. The blots were
then probed with various antibodies (details are given in
Supplemental Table S1). Immunofluorescence staining of mono-
layer cell cultures and 3D culture was done as previously described
[23].
RNA Extraction, RT-PCR, and Quantitative RT-PCR
The detailed procedures for RNA extraction RT-PCR and
primers sequences are described in the Supplemental Procedures
S1. Quantitative RT-PCR for EMT-associated genes was done
using SABiosciences (Frederick, MD) EMT-PCR Array according
to the manufacturer’s protocol.
Invasion, Soft Agar Colony Formation, Cell viability assay
and NF-kB activity
Invasion assay, cell viability assay to check the drug resistance
and NF-kB activity assay were performed as described previously
[3,13,19]. Soft agar assays were performed as described previously
[22]. Cultures were photographed, and the colonies with
diameters larger than 500 mm were counted using Image J
software (previously NIH image).
FACS Analysis
The anti-CD44 (clone G44-26), anti-CD24 (clone ML5), and
anti-CD45 (clone 2D1) antibodies used for FACS analysis were
obtained from BD Biosciences (San Jose, CA). The anti-CD326
(clone HEA-125) was obtained from Miltenyi Biotec (Auburn,
CA). Briefly, for each cell line, 5610
5 cells were aliquoted into 2
tubes; tube 1 was stained with IgG isotype controls for FITC, PE,
PerCP, and APC; tub e 2 was stained with anti-CD44-FITC, anti-
CD24-PE, anti-CD45-PerCP, and anti-CD326-APC. Cells were
incubated with appropriate antibodies at room temperature in
dark for 30 minutes, and then washed with PBS. Cells were
acquired by 4-color FACS Calibur (BD Biosciences), each sample
was acquired 10,000 cells for analysis.
Supporting Information
Procedures S1
Found at: doi:10.1371/journal.pone.0013390.s001 (0.03 MB
DOC)
Table S1 Antibodies used.
Found at: doi:10.1371/journal.pone.0013390.s002 (0.05 MB
DOC)
Table S2 Primers for RT-PCR.
Found at: doi:10.1371/journal.pone.0013390.s003 (0.04 MB
DOC)
Figure 6. Schematic of TG2-indued pathways involved in
promoting the metastatic phenotype. Inflammatory signals such
as generation of ROS
-, hypoxia, or TGF-b induce the expression of TG2
in epithelial cells. Induction of TG2 results in constitutive activation of
AKT, FAK and NF-kB, which can lead to the transcriptional regulation of
Snail1, Zeb1, and Twist. Expression of these transcription factors
represses the E-cadherin and induces the expression of fibronectin, N-
cadherin and vimentin. These changes result in transformation of
immotile epithelial cells to motile mesenchymal cells resulting in
altered cell-cell (homotypic) and cell-ECM (heterotypic) interactions
and offers metastatic niche to the cells in terms of increased
invasiveness, survival and self-renewing capacity by conferring stem
cell-like phenotype. TG2 expression also promotes anchorage-
independent growth.
doi:10.1371/journal.pone.0013390.g006
TG2-Induced EMT
PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13390Figure S1 Immunofluorescence showing the accumulation of
stress fibers in MCF10A-TG2 cells.
Found at: doi:10.1371/journal.pone.0013390.s004 (7.71 MB
TIF)
Figure S2 Phase-contrast images of acinar structures (4 and 12
days) formed as a result of MCF12A-vec and MCF12A-TG2 cell
culture in Matrigel-coated glass-slide chambers for indicated time
periods.
Found at: doi:10.1371/journal.pone.0013390.s005 (7.71 MB TIF)
Figure S3 Immunoblot showing the expression of TGF-b
receptor I & II, pSmad-2, and -3 and total smad-2 and 3 in
10A-vec and 10A-TG2 cells.
Found at: doi:10.1371/journal.pone.0013390.s006 (7.71 MB TIF)
Figure S4 Flow cytometric analysis of TG2-transfected (TG2)
and vector-alone (-vec) transfected mammary epithelial cells
(MCF12A) for CD44+/CD24-/low stem cell marker expression.
Found at: doi:10.1371/journal.pone.0013390.s007 (7.71 MB TIF)
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